文章名稱引用次數

• Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience28
• Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads28
• Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma23
• Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis22
• Radiomics to predict immunotherapy-induced pneumonitis: proof of concept19
• Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors18
• Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma18
• Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment15
• Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma14
• Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo13